Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD.
Di Mario F, Crafa P, Franceschi M, Rodriguez-Castro K, Baldassarre G, Ferronato A, Antico A, Panozzo MP, Franzoni L, Barchi A, Russo M, De Bortoli N, Ghisa M, Savarino E. Di Mario F, et al. Among authors: ferronato a. J Gastrointestin Liver Dis. 2021 Feb 12;30(1):25-29. doi: 10.15403/jgld-2952. J Gastrointestin Liver Dis. 2021. PMID: 33548125 Free article.
Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Scida S, Miraglia C, Penna A, Licci C, Rizzo GL, Pranzo G, Cassieri C, Brandimarte G, Picchio M, Di Mario F. Tursi A, et al. Among authors: ferronato a. Dig Dis. 2018;36(4):264-268. doi: 10.1159/000487391. Epub 2018 Apr 17. Dig Dis. 2018. PMID: 29669354
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.
Massimi D, Barberio B, Bertani L, Costa F, Ferronato A, Facchin S, Cardin R, Cingolani L, Casadei C, D'Incà R, Zingone F, Savarino EV. Massimi D, et al. Among authors: ferronato a. Therap Adv Gastroenterol. 2021 Jun 27;14:17562848211023384. doi: 10.1177/17562848211023384. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34249147 Free PMC article.
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
Barberio B, Cingolani L, Canova C, Barbieri G, Sablich R, Urbano MT, Bertani L, Costa F, Bodini G, Demarzo MG, Ferronato A, Buda A, Melatti P, Massimi D, Savarino EV, Zingone F. Barberio B, et al. Among authors: ferronato a. Therap Adv Gastroenterol. 2021 Jul 20;14:17562848211031420. doi: 10.1177/17562848211031420. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34349836 Free PMC article.
Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.
Rodriguez-Castro K, Crafa P, Franceschi M, Franzoni L, Brozzi L, Ferronato A, Morini A, Cuoco L, Baldassarre G, Pertoldi B, Di Mario F. Rodriguez-Castro K, et al. Among authors: ferronato a. Acta Biomed. 2022 Mar 14;93(1):e2022130. doi: 10.23750/abm.v93i1.11987. Acta Biomed. 2022. PMID: 35315405 Free PMC article.
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Tursi A, et al. Among authors: ferronato a. Ann Gastroenterol. 2019 Jul-Aug;32(4):392-399. doi: 10.20524/aog.2019.0377. Epub 2019 Apr 22. Ann Gastroenterol. 2019. PMID: 31263362 Free PMC article.
63 results